RedHill sells Talicia business to Apotex for $18 million upfront

RedHill Biopharma said Aug. 31 it sold its Talicia business to an Apotex subsidiary for $18 million in cash plus up to $35 million more tied to worldwide sales milestones. The deal gives RedHill immediate liquidity and funds a broader push into new gastrointestinal products as it tries to accelerate growth and move toward profitability.

Why it matters: - RedHill is turning its 70% stake in Talicia into immediate cash and possible future upside. - The company says the proceeds strengthen liquidity and fund the next phase of its commercial expansion. - The deal is intended to help RedHill broaden its gastrointestinal franchise and speed its path toward operational profitability.

What happened: - RedHill Biopharma announced Aug. 31 that it divested the Talicia business to a subsidiary of Apotex Health Corp. - Apotex will pay $18 million upfront. - RedHill can receive up to $35 million more in worldwide net sales milestone payments. - The transaction involves RedHill’s 70% interest in Talicia. - Apotex already owned the remaining 30% of Talicia through its prior acquisition of Cumberland Pharmaceuticals Inc.’s U.S. branded business.

The details: - RedHill said it received the $18 million cash payment at closing. - The company said the transaction unlocks resources for new, high-value, FDA-approved product opportunities. - RedHill said the sale supports expansion of its existing gastrointestinal commercial franchise into a larger business. - RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP. - Apotex is a Canadian-based global health company with a portfolio that includes generic, biosimilar, innovative branded pharmaceuticals and consumer health products. - Apotex is headquartered in Toronto and has regional offices in the United States, Mexico and India. - Apotex describes itself as the largest Canadian-based pharmaceutical company and a partner for pharmaceutical licensing and product acquisitions in the Americas.

Between the lines: - The deal simplifies RedHill’s ownership structure in Talicia by transferring the remaining stake to Apotex. - RedHill is signaling a shift away from a shared-ownership asset and toward products that can drive larger and faster revenue growth. - Talicia targets H. pylori infection, which RedHill linked to gastric cancer and stomach ulcers. - The transaction gives Apotex full control of a product it can pursue globally.

What's next: - RedHill said the cash will help support its commercial expansion strategy and future product opportunities. - The company said it expects the move to support revenue growth and a faster path to profitability. - Any additional proceeds will depend on Talicia’s worldwide net sales performance.

The bottom line: - RedHill has traded a legacy stake in Talicia for cash now and contingent payments later, while positioning the company for a broader commercial reset.